自2019年底以来，新型冠状病毒(新冠病毒)感染大流行已席卷全球。虽然目前的新冠病毒变异株的致病性和毒力已较原始株有所下降，大多数患者预后良好，但实体器官移植(SOT)受者人群为新冠病毒感染脆弱人群，即使全程接种新冠病毒疫苗，SOT受者感染新冠病毒的住院或死亡风险依然较高。SOT受者新冠病毒感染后其临床表现、诊断和治疗均与普通人群存在很大的特殊性，需要高度关注。目前尚缺乏针对SOT受者人群可供参考的新冠病毒感染诊疗领域的指南或共识。因此，参考《新型冠状病毒诊疗方案(试行第十版)》及国内外文献，编写团队撰写了《实体器官移植受者新型冠状病毒感染诊疗专家共识(2023年版)》。本共识基于国内外新冠病毒感染的循证医学证据，并经过专家多次研讨达成一致意见后撰写成文，形成21条推荐意见，为SOT受者感染新冠病毒的诊疗提供参考。

Since the end of 2019, the novel coronavirus infection pandemic has swept the world. Although the current novel coronavirus mutants have decreased in pathogenicity and virulence compared with the original strains, and most patients have a good prognosis, the solid organ transplant (SOT) recipients are vulnerable to novel coronavirus. And even with vaccination, the risk of hospitalization or death is still high in SOT recipients infected with novel coronavirus. What′s more, the clinical manifestations, diagnosis and treatment strategy of SOT recipients infected with novel coronavirus has its unique features, which need high attention. At present, there is a lack of guidelines or consensus in the diagnosis and treatment field of novel coronavirus for such a large number of SOT recipients. Therefore, referring to the "Diagnosis and treatment plan of coronavirus (Trial Version 10)" and global published literature, the writing team wrote the "Expert consensus on diagnosis and treatment of novel coronavirus infection in solid organ transplant recipients (2023 edition)" . This consensus was evidence-based written and reached by experts after multiple rounds of discussions, forming 21 recommendations, providing reference for the diagnosis and treatment of SOT recipients infected with novel coronavirus.